Eric Devroe - 05 Jun 2023 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role
Chief Operating Officer
Signature
/s/ Rasmus Holm-Jorgensen, Attorney-in-Fact
Issuer symbol
ACRV
Transactions as of
05 Jun 2023
Net transactions value
+$9,594
Form type
4
Filing time
06 Jun 2023, 16:15:49 UTC
Previous filing
16 Nov 2022
Next filing
16 Nov 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRV Common Stock Options Exercise $9,594 +9,225 +17% $1.04* 62,883 05 Jun 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRV Stock Option (Right to Buy) Options Exercise $0 -9,225 -8.7% $0.000000 96,615 05 Jun 2023 Common Stock 9,225 $1.04 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the shares subject to the option vested on October 5, 2021, and the remaining shares subject to the option vested or shall vest in 12 equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney